Form4insider filings, from the source

SEC Form 4 · accession 0001209191-17-009595

ReShape Lifesciences Inc. · RSLS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Period of report
Feb 8, 2017
Accepted (ET)
Feb 10, 2017 · 4:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001371217

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stockholding———0D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Director Option (Right to Buy)F3$7.12Feb 8, 2017A30,000AFeb 8, 2017Feb 8, 2027Common Stock30,00030,000D
Director Option (Right to Buy)F1,F2$325.50holding————Jul 31, 2025Common Stock2323D
Director Option (Right to Buy)F1,F3$52.50holding———May 4, 2016May 4, 2026Common Stock4242D

Explanation of responses

Remarks

EX 24: McDougal Power of Attorney Attached THIS FILING REFLECTS THE POST SPLIT NUMBERS OF ALL SHARES, OPTIONS AND SIMILAR INSTRUMENTS HELD BY THE REPORTING PERSON AS PREVIOUSLY REPORTED.